Stories about Patents/Copyright/Trademarks

Subscribe to topic

Subscribe to Patents/Copyright/Trademarks

21.05.2014 – 07:21
ams AG
EANS-Adhoc: ams AG / ams wins patent validity lawsuit launched by Melexis; existing patent infringement verdict against Melexis reinstated and in force
issuer: ams AG Tobelbader Strasse 30 A-8141 Unterpremstaetten phone: +43 3136 500-0 FAX: +43 3136 500-931211 mail: investor@ams.com WWW: www.ams.com sector: Technology ISIN: AT0000920863 indexes: stockmarkets: official dealing: SIX Swiss Exchange language: English ...
19.02.2013 – 09:15
LPKF Laser & Electronics AG
EANS-News: LPKF settles dispute about patent infringement in Korea
company: LPKF Laser & Electronics AG Osteriede 7 D-30827 Garbsen phone: +49(0)5131 7095 1382 FAX: +49(0)5131 7095 90 mail: investorrelations@lpkf.de WWW: http://www.lpkf.de sector: Machine Manufacturing ISIN: DE0006450000 indexes: TecDAX, CDAX, Prime All Share, Technology All Share stockmarkets: free trade: Hannover, Berlin, München, Hamburg, Düsseldorf, Stuttgart, regulated dealing/prime standard: Frankfurt language: ...
30.07.2012 – 07:31
AGENNIX AG i.L.
EANS-News: Agennix AG Announces Notice of Allowance for U.S. Patent Application Covering Use of Talactoferrin Alfa to Treat Non-Small Cell Lung Cancer and Renal Cancer in Combination with Other Treatments
company: AGENNIX AG Im Neuenheimer Feld 515 D-69120 Heidelberg phone: +49 89 8565 2693 FAX: +49 89 8565 2610 mail: ir@agennix.com WWW: http://www.agennix.com sector: Pharmaceuticals ISIN: DE000A1A6XX4 indexes: CDAX, Prime All Share, Technology All Share stockmarkets: free trade: Hannover, Berlin, München, ...
10.08.2011 – 08:17
AGENNIX AG i.L.
EANS-News: AGENNIX AG / Agennix Announces Issuance of European Patent Covering Use of Talactoferrin to Treat Cancer
company: AGENNIX AG Im Neuenheimer Feld 515 D-69120 Heidelberg phone: +49 89 8565 2693 FAX: +49 89 8565 2610 mail: ir@agennix.com WWW: http://www.agennix.com sector: Pharmaceuticals ISIN: DE000A1A6XX4 indexes: CDAX, Prime All Share, Technology All Share stockmarkets: regulated dealing/prime standard: Frankfurt, ...
17.06.2011 – 08:39
PUMA SE
EANS-Adhoc: PUMA AG Rudolf Dassler Sport / Arbitration Ruling regarding One-Time Payment of EUR98 Million in Spain repealed
issuer: PUMA AG Rudolf Dassler Sport Würzburger Strasse 13 D-91074 Herzogenaurach phone: +49 (0)9132 81 0 mail: investor-relations@puma.com WWW: http://about.puma.com/?lang=de sector: Consumer Goods ISIN: DE0006969603 indexes: Midcap Market Index, MDAX, CDAX, Classic All Share, HDAX, Prime All Share stockmarkets: ...
23.03.2011 – 08:06
AGENNIX AG i.L.
EANS-News: AGENNIX AG / Agennix AG Announces Issuance of U.S. Patent Covering Use of Talactoferrin to Treat Non-Small Cell Lung Cancer and Renal Cell Carcinoma
Further inquiry note: Barbara Mueller Manager, Investor Relations & Corporate Communications Phone: +49 (0)89 8565 2693 ir@agennix.com In the U.S.: Laurie Doyle Senior Director, Investor Relations & Corporate Communications Phone: +1 609 524 5884 laurie.doyle@agennix.com Additional media contact for Europe: MC ...
29.06.2010 – 19:30
PUMA SE
EANS-Adhoc: PUMA AG Rudolf Dassler Sport / Contingent Liability in relation with an Arbitration Ruling to grant PUMA all Trademark Rights in Spain
Further inquiry note: Ulf Santjer Telefon: +49 (0)9132 81-2489 E-Mail: Kerstin.Neuber@puma.com Branche: Consumer Goods ISIN: DE0006969603 WKN: 696960 Index: Midcap Market Index, MDAX, CDAX, Classic All Share, HDAX, Prime All Share Börsen: Frankfurt / regulated dealing/prime standard Berlin / free trade Hamburg / ...
27.04.2010 – 14:01
Epigenomics AG
EANS-News: Epigenomics AG Receives Allowance of Key Patent in the U.S.
Patent covers detection of colorectal cancer with Septin9 Biomarker Further inquiry note: Epigenomics AG Dr. Achim Plum Sen. VP Corporate Development Tel: +49 30 24345 368 achim.plum@epigenomics.com Branche: Biotechnology ISIN: DE000A0BVT96 WKN: A0BVT9 Index: Prime All Share, Technology All Share Börsen: Frankfurt / regulated dealing/prime standard Berlin / free ...
11.03.2010 – 16:01
Epigenomics AG
EANS-News: Epigenomics AG Receives Allowance for Key Technology Patent in Japan
Patent broadly covers HeavyMethyl, a core technology of Epigenomics molecular diagnostic products Further inquiry note: Epigenomics AG Dr. Achim Plum Sen. VP Corporate Development Tel: +49 30 24345 368 achim.plum@epigenomics.com Branche: Biotechnology ISIN: DE000A0BVT96 WKN: A0BVT9 Index: Prime All Share, Technology All Share Börsen: Frankfurt / regulated ...

1